Overview: A Targeted Approach to a Complex Neurodegenerative Challenge In a bid to address an emerging and controversial hypothesis in Alzheimer’s disease (AD) research, Lighthouse Pharmaceuticals announced the Phase 2 SPRING trial results for LHP588, a next-generation gingipain inhibitor, at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference. The company positions LHP588 as a…